We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System
News

CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System

CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System
News

CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellular Dynamics International (CDI) has announced their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process.

The partnership combines CDI’s induced pluripotent stem cell (iPSC)-derived heart cells, iCell™ Cardiomyocytes, with the xCELLigence™ RTCA System. The xCELLigence System is developed by ACEA and Roche Applied Science and marketed by Roche.

CDI has supplied purified human iCell Cardiomyocytes to ACEA for the evaluation experiments, in which the xCELLigence RTCA Cardio System was used to measure the effects of cardiac compounds with known electrophysiological and/or biochemical actions on the cells as well as drugs withdrawn from the market due to cardiac liability. The evaluation has been successfully completed, and the platform is in external beta testing at several pharmaceutical and academic institutions and will be made commercially available soon.

“CDI’s goal is to supply relevant human cellular tools to improve the efficiency and throughput of drug development pipelines,” said Chris Parker, CDI Chief Commercial Officer. “Our iCell Cardiomyocytes provide a biochemically and electrophysiologically relevant human model for discovery and testing, compared to current non-human, cadaveric, or immortalized cells lines. In addition, our industrialized manufacturing process enables us to supply homogeneous cells in the quantity, quality, and purity required to assess potential cardiac effects caused by drugs under development.”

“The xCELLigence RTCA Cardio System adds a new, cutting-edge product line to our non-invasive cell-based assays providing physiological relevant data. It allows our customers to study drug effects on the ultimate physiological function of cardiomyocytes: heart beating,” said Ruedi Stoffel, Life Cycle Leader Cellular Analysis at Roche Applied Science. “Also, the use of the xCELLigence RTCA Cardio System, together with iPSC-derived cardiomyocytes allows reducing animal testing via the use of innovative in vitro test systems.”

Dr. Xiaobo Wang, ACEA Vice President and CTO, stated, "We are excited that our technology allows for assessment of cardiac liability of drug candidates early in the drug development process. We look forward to working together with the scientists in this important area to test some of their compounds as part of our technology early access program prior to the launch of the RTCA Cardio System and provide them with important cardiotoxicity information about their compounds.”
Advertisement